Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

[1]  Chih-Wei Lin,et al.  Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure , 2018, Hepatology.

[2]  A. Tsubota,et al.  Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  N. Enomoto,et al.  Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection , 2017, Journal of Gastroenterology.

[4]  H. Mo,et al.  Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. , 2017, Journal of Hepatology.

[5]  A. Tsubota,et al.  Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy , 2017, Journal of Gastroenterology.

[6]  K. Chayama,et al.  Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan , 2017, Journal of Gastroenterology.

[7]  N. Sakamoto,et al.  Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment , 2016, Journal of clinical and translational hepatology.

[8]  T. Miyagishima,et al.  Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  H. Yoshiji,et al.  The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study , 2016, Journal of Gastroenterology.

[10]  K. Reddy,et al.  Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. , 2016, Gastroenterology.

[11]  T. Ishikawa,et al.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis , 2016, Journal of Gastroenterology.

[12]  F. Sato,et al.  Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C , 2016, Journal of Gastroenterology.

[13]  P. Messa,et al.  Pegylated Interferon Mono‐Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta‐Analysis , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[14]  D. Nelson,et al.  Erratum: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 45 chronic kidney disease (the C-SURFER study): A combination phase 3 study. (Lancet (2015) 386 (1537-45)) , 2015 .

[15]  T. Hassanein,et al.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.

[16]  Shang-Jyh Hwang,et al.  Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis , 2014, PloS one.

[17]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[18]  N. Izumi,et al.  2011 Japanese Society for Dialysis Therapy Guidelines for the Treatment of Hepatitis C Virus Infection in Dialysis Patients , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[19]  A. Macleod.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[20]  K. Nitta,et al.  Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan , 2008, Clinical and Experimental Nephrology.

[21]  B. Takkouche,et al.  The impact of hepatitis C virus infection on survival in dialysis patients: meta‐analysis of observational studies , 2007, Journal of viral hepatitis.

[22]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[23]  S. Greenland,et al.  Hepatitis C virus and death risk in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  N. Accortt,et al.  Hepatitis C infection is acquired pre-ESRD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[26]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[27]  F. Marumo,et al.  Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. , 2000, Journal of the American Society of Nephrology : JASN.